Brief: Adverum Biotechnologies Proceeds With IND Amendment For ADVM-022 Phase 2 Trial In Wet AMD After Receiving Requested Type C Meeting Feedback From FDA
06/04/2022 22:29
April 6 (Reuters) - Adverum Biotechnologies Inc ADVM.O :
* ADVERUM BIOTECHNOLOGIES PROCEEDS WITH IND AMENDMENT FOR
ADVM-022
PHASE 2 TRIAL IN WET AMD AFTER RECEIVING REQUESTED TYPE C
MEETING FEEDBACK FROM FDA
* ADVERUM - LOOKING FORWARD TO COMPLETING IND AMENDMENT FOR
ADVM-022 PHASE 2 TRIAL BY MID-2022, REMAIN ON TRACK TO INITIATE
PHASE 2 STUDY IN Q3 2022
Source text for Eikon: ID:nGNXbd9Dv8
Further company coverage: ADVM.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Adverum Biotechnologies
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Brief: Adverum Reminds Stockholders To Tender Their Shares Into The Offer By Lilly
Brief: Adverum Biotechnologies Inc - Are-Nc Region No. 21 Llc Terminates Certain Lease Agreement With Adverum Biotechnologies - SEC Filing
Eli Lilly bets on eye care with buyout of gene therapy developer Adverum (updated)